Chimeric Antigen Receptors (CARs) are engineered receptors that allow T cells to specifically target and destroy cancer cells. These synthetic receptors are designed to fuse an antigen-binding domain (usually derived from a monoclonal antibody) with T cell signaling domains. This enables T cells to recognize specific proteins on the surface of cancer cells, leading to targeted immune responses.
